Connective tissue disease in children

Robert L. Buka, Bari B. Cunningham

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

As our understanding of connective tissue disease expands, so too does our therapeutic armamentarium. We have learned that autoimmunity triggers inflammation through unchecked, proliferative cell-mediated inflammation. By targeting this arm of the cytokine cascade, it may be possible to arrest further progression. Several biologic agents, such as etanercept, alefacept, infliximab, efaluzimab, and, recently, adalimumab, have come to market for adult psoriasis and are now undergoing trials for juvenile SLE, psoriasis, and psoriatic arthritis. Of note, etanercept has been used successfully in juvenile rheumatoid arthritis for more than 10 years. These agents target cell-mediated inflammation through various mechanisms and hold great promise for the treatment of many of the disease states discussed above. Moreover, the biologies carry an improved side-effect profile not seen with traditional agents such as corticosteroids and will be central in the evolution of targeted therapeutics for these complex immunologic diseases.

Original languageEnglish
Pages (from-to)225-238
Number of pages14
JournalPediatric Annals
Volume34
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'Connective tissue disease in children'. Together they form a unique fingerprint.

Cite this